Literature DB >> 11551238

IL-18 in patients with multiple sclerosis.

J Losy1, A Niezgoda.   

Abstract

IL-18 is a cytokine which plays an important role in Th-1 response through its ability to induce IFN-gamma production in T cells and NK cells. The purpose of the study was to measure IL-18 levels in serum and CSF of 21 patients with the relapsing-remitting form of MS, 9 with active gadolinium enhancing lesions in MRI and 12 without enhancing lesions, and to compare results with control group consisting of 11 patients with diagnosis of neurasthenia and tension headache. IL-18 concentration in the CSF and sera was measured by ELISA. We found a highly significant increase of both IL-18 CSF and serum levels in MS patients in comparison with the control group. In patients with active MRI lesions the levels of IL-18 in CSF and serum were significantly higher in comparison with the levels found in patients without enhancing lesions. The results suggest involvement of IL-18 in immunopathogenesis of MS especially in the active stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551238     DOI: 10.1034/j.1600-0404.2001.00356.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  28 in total

1.  Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis.

Authors:  Sevim Karakas Celik; Zehra Safi Öz; Ahmet Dursun; Aysun Unal; Ufuk Emre; Salih Cicek; Fatih Mehmet Keni
Journal:  Mol Biol Rep       Date:  2014-01-09       Impact factor: 2.316

2.  The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18.

Authors:  Sushmita Jha; Siddharth Y Srivastava; W June Brickey; Heather Iocca; Arrel Toews; James P Morrison; Vivian S Chen; Denis Gris; Glenn K Matsushima; Jenny P-Y Ting
Journal:  J Neurosci       Date:  2010-11-24       Impact factor: 6.167

Review 3.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

4.  IL-18 gene promoter polymorphisms are only moderately associated with periodontal disease in Italian population.

Authors:  Francesco Saverio Martelli; Alessio Mengoni; Marialaura Martelli; Claudio Rosati; Elena Fanti
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

Review 5.  IL-18 in inflammatory and autoimmune disease.

Authors:  Saikiran K Sedimbi; Thomas Hägglöf; Mikael C I Karlsson
Journal:  Cell Mol Life Sci       Date:  2013-07-27       Impact factor: 9.261

6.  Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18.

Authors:  Maria A Argiriadi; Tao Xiang; Chengbin Wu; Tariq Ghayur; David W Borhani
Journal:  J Biol Chem       Date:  2009-06-24       Impact factor: 5.157

7.  Interleukin 18 activates MAPKs and STAT3 but not NF-κB in hippocampal HT-22 cells.

Authors:  Silvia Alboni; Claudia Montanari; Cristina Benatti; Manuel Sanchez-Alavez; Giovanna Rigillo; Joan M C Blom; Nicoletta Brunello; Bruno Conti; M Carmine Pariante; Fabio Tascedda
Journal:  Brain Behav Immun       Date:  2014-03-04       Impact factor: 7.217

8.  Is MS an inflammatory or primary degenerative disease?

Authors:  Jacek Losy
Journal:  J Neural Transm (Vienna)       Date:  2013-09-06       Impact factor: 3.575

Review 9.  Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.

Authors:  Falguni Baidya; Mariya Bohra; Aishika Datta; Deepaneeta Sarmah; Birva Shah; Priya Jagtap; Swapnil Raut; Ankan Sarkar; Upasna Singh; Kiran Kalia; Anupom Borah; Xin Wang; Kunjan R Dave; Dileep R Yavagal; Pallab Bhattacharya
Journal:  Immunology       Date:  2020-10-06       Impact factor: 7.397

10.  Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.

Authors:  Madhan Thamilarasan; Michael Hecker; Robert Hermann Goertsches; Brigitte Katrin Paap; Ina Schröder; Dirk Koczan; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  J Neuroinflammation       Date:  2013-10-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.